Skip to Content

Study of Bristol-Myers, AstraZeneca Diabetes Drug

From Associated Press (June 26, 2011)

NEW YORK -- Two pharmaceutical companies said Sunday that a potential new drug for Type 2 diabetes patients holds promise after a late-stage clinical study.

Bristol-Myers Squibb Co. and AstraZeneca PLC said that adults with Type 2 diabetes who were treated with a compound called dapagliflozin had more success at sustaining lower blood sugar levels than those who took a common treatment called glipizide during a two-year study.

In the studies, both dapagliflozen and glipizide were added to oral diabetic drug metformin.

Patients who took dapagliflozin were also more likely to lose weight and have fewer episodes of lower than normal levels of blood glucose during the two years, the companies said. However, patients taking dapagliflozin also reported a higher risk of genital infections and urinary tract infections.

The Food and Drug Administration is reviewing the compound. Bristol-Myers Squibb and AstraZeneca have been working together on drugs for Type 2 diabetes since 2007.

In Type 2 diabetes, the most common form of diabetes, the body doesn't produce enough insulin or cells ignore or don't use the insulin. In Type 1 diabetes the body doesn't produce insulin.


Posted: June 2011